Reporting a Population Pharmacokinetic–Pharmacodynamic Study: A Journal’s Perspective

被引:0
|
作者
Kris M. Jamsen
Sarah C. McLeay
Michael A. Barras
Bruce Green
机构
[1] Model Answers Pty Ltd,
[2] Royal Brisbane and Women’s Hospital,undefined
来源
Clinical Pharmacokinetics | 2014年 / 53卷
关键词
Supplementary File; Population Pharmacokinetic Model; Objective Function Value; Visual Predictive Check; Sampling Schedule;
D O I
暂无
中图分类号
学科分类号
摘要
The key purpose of performing pharmacometric research is to aid optimization of drug dosing strategies. The statistical techniques required for this research are advanced, which can make interpretation of results difficult to convey to the target audience if they are unfamiliar with pharmacometric concepts. This article provides a basic guide for authors who wish to publish pharmacometric analyses in peer-reviewed journals. This guide is intended to enhance the readability, reproducibility and understanding of the work for a general readership, which may include clinicians, pharmacists and pharmacometricians. Presentation techniques and examples are offered, as well as a checklist of suggested contents for the manuscript.
引用
收藏
页码:111 / 122
页数:11
相关论文
共 50 条
  • [31] Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design
    Reddy, Micaela B.
    Yang, Kuo-Hsiung
    Rao, Gauri
    Rayner, Craig R.
    Nie, Jing
    Pamulapati, Chandrasena
    Marathe, Bindumadhav M.
    Forrest, Alan
    Govorkova, Elena A.
    PLOS ONE, 2015, 10 (10):
  • [32] Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study
    Liang, Hao
    Deng, Zhenling
    Niu, Shu
    Kong, Weijie
    Liu, Yang
    Wang, Song
    Li, Haiyan
    Wang, Yue
    Zheng, Danxia
    Liu, Dongyang
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [33] Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a rheumatologist's perspective
    Day, RO
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (06) : S59 - S62
  • [34] Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective
    Brune, K
    Neubert, A
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (06) : S51 - S57
  • [35] Exploring inductive linearization in population pharmacokinetic and pharmacodynamic models
    Fidler, Matt
    Xiong, Yuan
    Schoemaker, Rik
    Wilkins, Justin
    Trame, Mirjam N.
    Post, Teun
    Hooijmakers, Richard
    Wang, Wenping
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S116 - S116
  • [36] A PHARMACODYNAMIC AND PHARMACOKINETIC STUDY OF TOLAZOLINE IN THE NEONATE
    MONIN, P
    VERT, P
    MORSELLI, PL
    DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1982, 4 : 124 - 128
  • [37] A Population Pharmacokinetic and Pharmacodynamic Model of CKD-519
    Kim, Choon Ok
    Jeon, Sangil
    Han, Seunghoon
    Park, Min Soo
    Yim, Dong-Seok
    PHARMACEUTICS, 2020, 12 (06) : 1 - 14
  • [38] Strategies for developing Alzheimer’s disease treatments: application of population pharmacokinetic and pharmacodynamic models
    Dong Wook Kang
    Seok-jin Cho
    Go-Wun Choi
    Hea-Young Cho
    Journal of Pharmaceutical Investigation, 2022, 52 : 519 - 538
  • [39] Population Pharmacokinetic-Pharmacodynamic Model of Topiramate's Effect on Cognition in Healthy Volunteers
    Lim, Chay Ngee
    Marino, Susan E.
    Brundage, Richard C.
    Birnbaum, Angela K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S56 - S56
  • [40] Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients
    Esmaeili, Tayebeh
    Rezaee, Mahmood
    Abdar Esfahani, Morteza
    Davoudian, Azadeh
    Omidfar, Dariush
    Rezaee, Saeed
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (08) : 1284 - 1292